Abstract
Objective
The aim of this study is to estimate the percentage of patients with metastatic ovarian, fallopian tube, and primary peritoneal cancer requiring ultra-radical surgery to achieve cytoreduction to less than 1 cm (optimal) or no macroscopic residual disease (complete).
Methods
Perioperative data were collected prospectively on consecutive patients undergoing elective cytoreductive surgery for metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer at the Norfolk and Norwich University Hospital, a tertiary referral cancer centre in the United Kingdom from November 2012 to June 2016.
Results
Over a 42-month period, 135 consecutive patients underwent cytoreductive surgery for stage IIIC and IV ovarian, fallopian tube, or primary peritoneal cancer. The median age of the patients was 69 years. 47.4% of the patients underwent diaphragmatic peritonectomy and/or resection, 20% underwent splenectomy, 14.1% had excision of disease from porta hepatis and celiac axis, and 5.2% of the patients had gastrectomy. Cytoreduction to no macroscopic visible disease (complete) and to disease with greater tumour diameter of less than 1 cm (optimal) was achieved in 54.1 and 34.1% of the cases, respectively. Without incorporating surgical procedures in the upper abdomen (‘ultra-radical’), the combined rate of complete and optimal cytoreduction would be only 33.3%.
Conclusions
Up to 50.4% of the patients in this study required at least one surgical procedure classified as ultra-radical, emphasizing the importance of cytoreductive surgery in the upper abdomen in management of women with stage IIIC and IV ovarian, fallopian tube, and primary peritoneal cancer.
Similar content being viewed by others
References
Ovarian cancer incidence statistics (2016) Cancer research UK. Accessed 15 Jun 2016
Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S192. doi:10.1016/S0020-7292(06)60033-7
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244. doi:10.1002/cncr.24149
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27(9):1419–1425. doi:10.1200/JCO.2008.19.1684
Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A (2010) Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 17(6):1642–1648. doi:10.1245/s10434-010-0964-9
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114(1):26–31. doi:10.1016/j.ygyno.2009.03.018
Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130(3):493–498. doi:10.1016/j.ygyno.2013.05.040
Ovarian Cancer (2011) National Institute for Health and Clinical Excellence UK NICE Clinical Guideline 122
Ultra-radical (extensive) surgery for advanced ovarian cancer (2013) National Institute for Health and Clinical Excellence UK NICE interventional procedure guidance (IPG470). https://www.nice.org.uk/guidance/ipg470. Accessed 11 Dec 2016
Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS (2010) The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecol Oncol 116(3):351–357. doi:10.1016/j.ygyno.2009.11.022
Fotopoulou C, Jones BP, Savvatis K, Campbell J, Kyrgiou M, Farthing A, Brett S, Roux R, Hall M, Rustin G, Gabra H, Jiao L, Stumpfle R (2016) Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. Arch Gynecol Obstet 294(3):607–614. doi:10.1007/s00404-016-4080-3
Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G, Dell’Anna T, Fossati R, Floriani I, Rossi RS, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, Mangioni C (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97(8):560–566. doi:10.1093/jnci/dji102
Bristow RE, del Carmen MG, Kaufman HS, Montz FJ (2003) Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 197(4):565–574. doi:10.1016/S1072-7515(03)00478-2
Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108(2):276–281. doi:10.1016/j.ygyno.2007.10.022 (S0090-8258(07)00862-1 [pii])
Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103(2):559–564. doi:10.1016/j.ygyno.2006.03.051
Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90(2):390–396
Bian C, Yao K, Li L, Yi T, Zhao X (2016) Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Arch Gynecol Obstet 293(1):163–168. doi:10.1007/s00404-015-3813-z
Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for R, Treatment of Cancer-Gynaecological Cancer G, Group NCT (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953. doi:10.1056/NEJMoa0908806
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249–257. doi:10.1016/S0140-6736(14)62223-6
Barton DP, Adib T, Butler J (2013) Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial ovarian cancer (PAEOC): a questionnaire survey. Gynecol Oncol 131(2):347–351. doi:10.1016/j.ygyno.2013.08.007
Iyer R, Gentry-Maharaj A, Nordin A, Burnell M, Liston R, Manchanda R, Das N, Desai R, Gornall R, Beardmore-Gray A, Nevin J, Hillaby K, Leeson S, Linder A, Lopes A, Meechan D, Mould T, Varkey S, Olaitan A, Rufford B, Ryan A, Shanbhag S, Thackeray A, Wood N, Reynolds K, Menon U (2015) Predictors of complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOC-UK gynaecological oncology surgical outcomes and complications). Br J Cancer 112(3):475–484. doi:10.1038/bjc.2014.630
Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107(1):77–85. doi:10.1097/01.AOG.0000192407.04428.bb
Chi DS, Ramirez PT, Teitcher JB, Mironov S, Sarasohn DM, Iyer RB, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Brown CL, Aghajanian C, Gershenson DM, Hoskins WJ, Hricak H, Barakat RR (2007) Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J Clin Oncol 25(31):4946–4951. doi:10.1200/JCO.2007.12.2317
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI (2016) Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol 143(1):3–15. doi:10.1016/j.ygyno.2016.05.022
Thrall MM, Goff BA, Symons RG, Flum DR, Gray HJ (2011) Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 118(3):537–547. doi:10.1097/AOG.0b013e31822a6d56
Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972):977–1010. doi:10.1016/S0140-6736(14)62038-9
du Bois A, Harter P (2010) Understanding and optimizing the potential role of surgical debulking in advanced epithelial ovarian cancer. Am Soc Clin Oncol Ed Book e13–e17
Acknowledgements
No grants or funds were used to complete this project.
Financial support
None required.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Research involving human participants and/or animals
All procedures being performed were part of routine practice in our institution. The data collection and analysis were done in keeping with our institutional clinical governance protocols, and the results were presented to the Trust Board meeting as recommended by NICE Interventional Procedure Guidance 470.
Informed consent
Informed consent was obtained from all individual participants included in this study; this consent was for the procedures being performed as part of their routine care.
Funding
This study did not receive or require any funding.
Rights and permissions
About this article
Cite this article
Turnbull, H.L., Akrivos, N., Wemyss-Holden, S. et al. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer. Arch Gynecol Obstet 295, 681–687 (2017). https://doi.org/10.1007/s00404-016-4265-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-016-4265-9